HOME > BUSINESS > Zydus Cadila starts Phase II trial on anemia drug for kidney patients

Zydus Cadila starts Phase II trial on anemia drug for kidney patients

Zydus said it started phase II trial on its anemia drug candidate ZYAN1.

The drug, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is being tested as a treatment for anemia associated with chronic kidney disease (CKD).

The move follows successful Phase 1 trials. A drug has to go through three phases of clinical trials before it is submitted for approval.

Phase I trials of ZYAN1 were conducted in Australia and India, and results were recently published in Clinical Pharmacokinetics.

“ZYAN1 was safe and well-tolerated in healthy volunteers following single escalating oral doses (10-300 mg) and multiple escalating oral doses (100-300 mg).

The measurement of serum erythropoietin (EPO) levels in healthy volunteers confirmed the pharmacodynamic effect as EPO increased with increasing ZY AN1 doses in relation to placebo,” the company said.

The drug is supposed to inhibit hypoxia-inducible factor prolyl hydroxylase and thereby increase the natural production of hemoglobin and red blood cells in anemic patients.

ZYAN1 has been shown to improve iron mobilization and has the potential to reduce or eliminate the need for iron supplementation, the company said.

“We have observed desired pharmacokinetic & safety profile in addition to positive signals in biomarker responses, including erythropoietin increase with ZYAN1 in the two phase I trials that were conducted in Australia and India” said, Pankaj Patel, Chairman & Managing Director, Zydus Cadila.

“ZYANl has the potential to bring about a paradigm shift in the management of patients with anemia as it could provide an oral, safer alternative to currently available erythropoietin-stimulating agents (ESAs), which are associated with an increased risk of CV events, and must be given via injections. Zydus is committed to bring this therapy to millions of patients suffering from anemia,” he added.

Anemia is a global public health problem affecting both developing and developed countries. Anemia commonly arises in kidney disease patients, because the kidneys no longer produce sufficient amounts of erythropoietin, a hormone which stimulates red blood cell production.

Symptoms of anemia may include fatigue, skin pallor, shortness of breath, light-headedness, dizziness or a fast heartbeat. The Global ESA Market was estimated at USD 7 billion worldwide.

Follow ULTRA.news
Zydus Cadila gets approval for two drugs in the US Zydus Cadila said it received the final regulatory approval to market anti-sleep drug Modafinil in the US, and tentative approval for bladder control drug Solifenacin Succinate.Unlike a final approval, tentative approvals don't allow the grantee to sell the drugs in the US m...
Lupin gets nod to launch Metronidazole antibiotic in the US Lupin said it received final approval to market a generic version of G.D. Searle LLC Flagyl antibiotic tablets in the US.Flagyl tablets had US sales of USD 44.1 millionLupin’s Metronidazole Tablets USP, 250 mg and 500 mg are the AB rated generic equivalent of the drug. ...
Lupin gets UDFDA nod for generic version of Pfizer’s acne drug Pharma company Lupin said it received final approval from the US Food and Drug Administration for launching a generic version of Pfizer Inc.'s acne drug Vibra-Tabs.Doxycycline Hyclate Tablet 100 mg had US sales of USD 149.9 million per year, the company said.Doxycycline ...
Panacea Biotec to supply heart drug to Apotex for US market Pharma company Panacea Biotec said it has signed an agreement to supply a generic version of Eli Lilly's Effient heart drug to Apotex, the largest Canadian-owned pharmaceutical company.The drug will be sold by Apotex in the US market."Under the terms of the agreement, Ap...
Zydus Cadila to launch immuno-suppressant in the US Pharma giant Zydus Cadila said it received final approval from the USFDA to market immunonsuppressant Mycophenolate Mofetil injection.The drug is indicated for use in combination with other drugs i.e., cyclosporine and corticosteroids for the prophylaxis of organ rejection ...
Jubilant Life Sciences gets US-FDA approval for pain drug Pharma company Jubilant Life Sciences Ltd said it received final approval to sell pain drug Indomethacin in the US.The drug, which is also sold as Indocin by Iroko in the US, is a nonsteroidal anti-inflammatory drug used for the treatment of moderate to severe inflammation a...
Glenmark Pharma gets USFDA approval for generic version of Mylan’s anti-inflammation ointment Glenmark Pharmaceuticals said it has got the US FDA approval to sell the generic version of corticosteroid ointment Kenalog from Mylan Pharmaceuticals.The primary ingredient is triamcinolone, a corticosteroid that reduces the actions of chemicals in the body that cause inflam...
Aurobindo Pharma HIV drug gets USFDA approval under PEPFAR Aurobindo Pharma said it received tentative approval for its for anti-HIV drug Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate under the U.S. President's Emergency Plan for AIDS Relief or PEPFAR.The approved product is used for the treatment of HIV-1 infection alon...
Zydus Cadila gets USFDA nod for chemo, BP drugs Zydus Cadila said it has received approval from the US Food and Drug Administration to market chemotherapy drug Temozolomide and blood pressure drug Nadolol.Temozolomide will be made available in six doses from 5 mg to 250 mg.It is used in the management of brain tumors....
Strides Shasun to launch allergy drug in the US Pharma company Strides Shasun said it had received approval allergy drug Cetirizine Hydrochloride in the US."The US market for Cetirizine Hydrochloride Capsules (Softgel) is approximately USD 60 mln, with only one other generic player," the company said."The product is re...
Glenmark gets US FDA approval for generic version of Daiichi Sankyo’s hypertension drug Glenmark Pharmaceuticals said it got approval from US authorities to launch a generic version of Daiichi Sankyo's hypertension drug Azor in various dosages.The drug had annual sales of approximately $211.6 million as of May.The approval was obtained from United States Foo...
Jubilant Life Sciences gets USFDA nod for anti-depressant Jubilant Life Sciences said it received final approval from US authorities to launch a generic version of Valeant's anti-depressant Wellbutrin.The approval from FDA is for introducing Bupropion Hydrochloride tablets in 150 mg and 300 mg doses.The drug is used for the tre...
Lupin launches eye drug in the US Pharma company Lupin said it launched Moxifloxacin Hydrochloride eye solution in the US.Lupin's Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.'s Vigamox Ophthalmic solution.It is indicated for...
Zydus Cadilla gets preliminary USFDA nod for diabetes treatment Zydus Cadila has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Tablets used for controlling blood sugar levels."This is a fixed dose combination of two anti-diabetic drugs indicated for Type II diabetes mellitus and will be p...
Glenmark Pharma gets UK OTC approval for anti-malarial medicine Glenmark Pharmaceuticals said it received approval from UK authorities for to sell its Maloff Protect anti-malarial medication without prescription.It contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK.The Me...
Strides Shasun gets USFDA nod for nausea drug Pharmaceutical company Strides Shasun said it received approval from the United States Food & Drug Administration to sell nausea drug Promethazine Hydrochloride in the country.The US market for Promethazine Hydrochloride tablets is approximately USD 17 Million.It will be ...
Zydus Cadila gets approval for obesity drug in USA Zydus Cadila said it received the final approval from the US FDA to market obesity drug Phentermine Hydrochloride.The drug will be marketed in the form of orally disintegrating tablets in strengths of 15 mg, 30 mg, and 37.5 mg.The drug is used to treat obesity in people w...
Zydus Cadila gets nod to sell ADHD drug in USA Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals received final approval from the US Food and Drug Administration to sell generic drug Dextroamphetamine Sulfate.Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyp...
Zydus Cadila to sell urine leakage drug in US Zydus Cadila said it received the final approval to sell urine leakage drug Oxybutynin Chloride in the US market.The annual US sales of the drug is about $150.9 million, it said.The US FDA approved dosages of 5 mg, 10 mg, and 15mg. The drug is largely available in generic...
Zydus Cadila gets USFDA nod for Hepatitis B drug Zydus Cadila has received the final approval from the the US Food and Drug Administration to market Hepatitis B drug Entecavir.The drug has sales of $166.3 million in the US, and will be sold in 0.5 mg and 1 mg dosage.It will be produced at the group's formulations manufa...
Glenmark gets USFDA approval for generic joint-pain drug in US Glenmark Pharmaceuticals said it received final approval from the United States Food & Drug Administration for marketing a generic version of joint-pain drug Indocin of Iroko Pharmaceuticals.The drug has annual sales of approximately $6.3 million.With this, Glenmark’s ...
Alembic Pharma to launch generic version of AstraZeneca heart drug in USA Alembic Pharmaceuticals said it received approval from the US Food & Drug Administration for selling a generic equivalent of AstraZeneca's heart drug Atacand.Approval was granted for the sale of candesantan cilexetil in the dosage of 32 mg.Candesartan cilexetil is used ...
Zydus Cadila gets USFDA approval for generic version of popular migraine drug Zydus Cadila said it received final approval from the US Food and Drug Administration to market migraine drug Eletriptan Hydrobromide in the US.The drug is currently marketed and manufactured by Pfizer Inc and sold in the US and Canada under the brand name Relpax.The two...
Aurobindo Pharma launches kidney drug in the US Aurobindo Pharma said it received final approval from the US Food & Drug Administration to manufacture generic version of kidney drug Renvela from Genzyme.Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm is being launched immediately, the company said.The drug had ...
Lupin gets USFDA approval for pain relief drug Pharma Major Lupin said received final approval for launching a generic version of Mallinckrodt Inc.'s Roxicodone Tablets in the United States.The drug is used for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are...